Larimar Therapeutics Stock Dips After Open-Label Extension Study Data Release
Nomlabofusp shows promise increasing frataxin levels in Friedreich’s Ataxia patients, according to early study data. However, serious adverse events in two participants and a small sample size warrant further research and larger trials.
Larimar Therapeutics Stock Dips After Open-Label Extension Study Data Release Read More »